Myocardial Ischemia and Infarction  by Ambrose, John A.
M
J
F
A
T
t
t
c
p
b
c
l
z
7
b
h
n
O
i
t
t
d
1
w
3
i
m
a
m
v
s
d
g
a
o
p
t
A
C
b
d
T
g
t
p
(
b
Journal of the American College of Cardiology Vol. 47, No. 11 Suppl D
© 2006 by the American College of Cardiology Foundation ISSN 0735-1097/06/$32.00
Pyocardial Ischemia and Infarction
ohn A. Ambrose, MD, FACC
ublished by Elsevier Inc. doi:10.1016/j.jacc.2006.04.013resno, California
a
p
T
a
l
m
p
i
a
5
a
s
c
i
t
m
w
r
b
b
a
f
n
s
G
r
t
h
p
o
h
d
b
p
S
f
t
o
p
i
a
p
u
a
b
sNTITHROMBOTIC STRATEGIES
he international Reduction of Atherothrombosis for Con-
inued Health (REACH) registry was an enormous under-
aking, involving more than 68,000 stable patients with
oronary artery disease (CAD), cerebral vascular disease,
eripheral arterial disease, and/or multiple atherothrom-
otic risk factors (1). At baseline, most of the patients in this
ontemporary registry were on optimal therapy: 75% on
ipid-lowering therapy, 73% on angiotensin-converting en-
yme (ACE) inhibitors or angiotensin receptor blockers,
9% on antiplatelet therapy, and nearly one-half were taking
eta-blockers.
This large global registry gives us an idea of the natural
istory of these patients, whether they have disease or just
umerous risk factors. The results were a little discouraging.
ne-year follow-up data, available in 92% of patients,
ndicated that cardiovascular (CV) death, myocardial infarc-
ion (MI), stroke, or hospitalization occurred in 12.9% of
he REACH registry subjects. In patients with established
isease, the overall incidence of these major events was
4.5%, whereas in those with risk factors only, the event rate
as 5.4%. Hard events—death, MI, or stroke—occurred in
.5% of the registry patients at one year, although the
ncidence of these hard events increased in patients with
ultiple sites of established disease. Bleeding rates were low
nd intervention rates were modestly elevated, although
ost of the interventions were performed in peripheral
essels. The investigators concluded that atherothrombosis
hould be addressed as a global disease and events need to be
ecreased; the high event rate was disconcerting given the
ood therapy most patients received, and this requires
ttention.
In various randomized trials, investigators have focused
n antithrombotic approaches in both stable and unstable
atients with CAD. In the Clopidogrel for High Athero-
hrombotic Risk, Ischemic Stabilization, Management, and
voidance (CHARISMA) trial, patients with established
V disease at baseline or at high risk for an adverse event
ecause of multiple risk factors were randomized to low-
ose aspirin alone versus aspirin plus clopidogrel 75 mg/day.
here was no significant difference between these two
roups on follow-up, but the addition of clopidogrel when
here was evidence of established CV disease at baseline
roduced a 12% reduction in the primary efficacy end point
6.9% vs. 7.9%; p  0.046) (2). Given the small amount of
enefit seen, we clearly need to know the cost efficacy of thisCFrom the UCSF-Fresno, Fresno, California.pproach before we routinely prescribe clopidogrel to all
atients with CV disease.
In the Acute Catheterization and Urgent Intervention
riage Strategy (ACUITY) trial, researchers evaluated hep-
rin plus glycoprotein (GP) IIb/IIIa inhibition versus biva-
irudin with GP IIb/IIIa inhibition or bivalirudin alone in
oderate- to high-risk acute coronary syndrome (ACS)
atients undergoing an early invasive strategy. The trial
nvolved 13,800 patients; 99% of the patients underwent
ngiography at a median of 20 h after hospital admission,
6% underwent percutaneous coronary intervention (PCI),
nd 11% underwent subsequent coronary artery bypass graft
urgery (3). The primary end points included an ischemic
omposite end point (death, MI, or unplanned revascular-
zation); a composite of net clinical benefit, which included
he ischemic composite end point plus major bleeding; or
ajor bleeding by itself; all were calculated at 30 days.
Statistical analysis was performed for noninferiority as
ell as for superiority, and these were both predefined. The
esults showed that the ischemic composite was similar
etween groups, but major bleeding was seen less in the
ivalirudin alone group, including retroperitoneal bleeds,
ccess site bleeds, a decrease in hemoglobin, and the need
or transfusion. Bivalirudin plus a GP IIb/IIIa inhibitor was
oninferior to the heparin arm. The net clinical benefit was
uperior in the bivalirudin alone group versus heparin plus
P IIb/IIIa inhibition, based solely on the lower bleeding
ates with bivalirudin (Fig. 1). In conclusion, the investiga-
ors suggested that bivalirudin can be substituted for either
eparin or enoxaparin in these moderate- to high-risk ACS
atients undergoing an early invasive strategy with the use
f GP IIb/IIIa inhibitors. However, compared with either
eparin or enoxaparin with GP IIb/IIIa inhibition, bivaliru-
in alone has a greater net clinical benefit because of less
leeding.
Another study dealing with high-risk ACS patients was
resented by Dr. Adnan Kastrati, for the Intracoronary
tenting and Antithrombotic Regimen: Rapid Early Action
or Coronary Treatment (ISAR-REACT 2) trial (4). In this
rial, patients with rest pain and either ST-segment changes
r an elevated baseline troponin set to undergo PCI were all
retreated with clopidogrel 600 mg at least 2 h before
ntervention. They were then randomized to standard-dose
bciximab versus placebo at the time of intervention. The
rimary efficacy end point was a composite of death, MI, or
rgent revascularization within 30 days, and safety was
ssessed as Thrombolysis In Myocardial Infarction (TIMI)
leeding. In the 2,022 patients randomized, abciximab
ignificantly reduced the end point from 11.9% to 8.9%.
linical benefit was seen only in the group with a baseline
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ACC 2006 Annual Session Highlights June 6, 2006:D13–7levated troponin level, and in this group, there was an
bsolute 5.5% reduction with the use of abciximab. Of some
urprise was the fact that there was no increase in bleeding
ith abciximab.
Dr. Salim Yusuf presented the Organization to Assess
trategies for Ischemic Syndromes-6 (OASIS-6) trial,
hich involved 12,092 ST-segment elevation myocardial
nfarction (STEMI) patients treated with either thrombo-
ytic therapy or PCI within 12 h of symptom onset (5). It
as a randomized double-blind comparison of fondaparinux
.5 mg daily versus standard-dose unfractionated heparin in
atients for whom heparin was indicated; or, for those
atients with a contraindication to unfractionated heparin,
he comparison was between fondaparinux 2.5 mg daily
ersus placebo. The heparin was given for two days, the
ondaparinux for nine days.
The primary efficacy end point was death or re-infarction
t 30 days, and the safety end point was severe bleeding.
rimary PCI was performed in 31% of patients, with lytic
herapy used in 45%, and no reperfusion therapy at all in
Abbreviations and Acronyms
ACE  angiotensin-converting enzyme
ACS  acute coronary syndrome
ACUITY  Acute Catheterization and Urgent
Intervention Triage Strategy
CAD  coronary artery disease
CHARISMA  Clopidogrel for High
Atherothrombotic Risk, Ischemic
Stabilization, Management, and
Avoidance
CV  cardiovascular
ECG  electrocardiogram
GFR  glomerular filtration rate
GP  glycoprotein
ExTRACT  Enoxaparin and Thrombolysis
Reperfusion for Acute Myocardial
Infarction Treatment
ISAR-REACT  Intracoronary Stenting and
Antithrombotic Regimen: Rapid Early
Action for Coronary Treatment
LDL  low-density lipoprotein
MI  myocardial infarction
NCEP  National Cholesterol Education
Program
OASIS  Organization to Assess Strategies for
Ischemic Syndromes
PEACE  Prevention of Events with
Angiotensin-Converting Enzyme
Inhibition
PCI  percutaneous coronary intervention
PTCA  percutaneous transluminal coronary
angioplasty
REACH  Reduction of Atherothrombosis for
Continued Health
STEMI  ST-segment elevation myocardial
infarction
TIMI  Thrombolysis In Myocardial
Infarction3% of patients. At 30-day follow-up, fondaparinux re-
I
Iuced the incidence of death or re-infarction (9.7% vs.
1.2%; p  0.008). Throughout the trial, there was a
tatistically significant decrease in mortality with fondapa-
inux. The benefit was only seen among patients undergoing
hrombolytic therapy or no reperfusion; PCI patients
howed no benefit. The OASIS-6 investigators reported a
endency for fewer severe bleeding events (p  0.13) with
ondaparinux and a significant reduction in cardiac tampon-
de (p  0.02) in the fondaparinux group. They concluded
hat for STEMI patients not undergoing primary PCI,
ondaparinux as used in this trial reduced mortality and
e-infarction without increasing severe bleeding.
The STEMI patients also were the focus of the
noxaparin and Thrombolysis Reperfusion for Acute
yocardial Infarction Treatment-Thrombolysis In Myo-
ardial Infarction 25 (ExTRACT-TIMI 25) study, which
nvolved 20,479 patients randomized 6 h after onset
nd treated with any fibrinolytic agent (6). Patients
eceived either enoxaparin for 7 days, which was age-
djusted with a lower dose for patients 75 years old, or
nfractionated heparin for at least 48 h. The primary
fficacy end point was all-cause death or nonfatal re-
nfarction at 30 days; the safety end point was major
leeding as in the OASIS-6 trial.
At 30 days, death or MI was significantly reduced with
noxaparin treatment, as was death, MI, or urgent revascu-
arization; nonfatal MIs also were reduced 33% with the
tudy drug (Table 1). Major bleeds, however, increased from
.4% to 2.1% with enoxaparin, although there was no
ncrease in intracranial hemorrhages, which were found in
bout 0.7% of the patient population. Antman et al. (6)
oncluded that for STEMI patients, enoxaparin for 7 days
as superior to unfractionated heparin for 48 h.
I agree very much with the conclusions; both STEMI
tudies suggest that long-term antithrombins may be
eeded with fibrinolytic therapy and not just for the usual
ne or two days of heparin therapy. However, there will
ikely be less impact from these trials in the U.S. and in
11.7 11.8
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Heparin +
GP IIb/IIIa
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GP IIb/IIIa
Bivalirudin 
alone
igure 1. Acute Catheterization and Urgent Intervention Triage Strategy
rial (ACUITY): 30-day composite net clinical benefit (death, myocardial
nfarction, revascularization for ischemia, or major bleeding), showing
uperiority of bivalirudin alone versus heparin plus glycoprotein (GP)
Ib/IIIa inhibitors (p  0.015). Combination of bivalirudin and GP
Ib/IIIa inhibitors was noninferior to heparin plus GP IIb/IIIa inhibitors.
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June 6, 2006:D13–7 ACC 2006 Annual Session Highlightsther countries where primary PCI or early post-MI an-
iography is the standard of therapy.
AD AND RENAL DYSFUNCTION
dditional abstracts presented dealt with the prognosis or
herapeutic options for patients with CAD and reduced
enal function. The Prevention of Events with Angiotensin-
onverting Enzyme Inhibition (PEACE) trial evaluated
he effect of ACE inhibition on mortality in 8,290 stable
atients; this new analysis evaluated the effect of reduced
enal function (7). Patients were randomized to trandolapril,
p to 4 mg/day, or placebo, with a primary end point of
eath on follow-up. For the one-sixth of the population
ith reduced glomerular filtration rates (GFRs), defined as
60 mg/ml, there was a 27% reduction in mortality with
randolapril, although the overall trial showed no mortality
dvantage for the ACE inhibitor. Patients with low GFRs
re often excluded from ACE inhibitor trials, but this study
uggests that these are the patients most likely to benefit
rom ACE inhibition using trandolapril. Furthermore, this
tudy and others presented at this meeting promote the
oncept that we should be routinely calculating creatinine
learances in our patients and not just simply relying on a
erum creatinine level.
The TIMI study group looked at data from 13,140
on–ST-segment elevation ACS patients from five TIMI
rials, assessing them for both diabetes and renal insuffi-
iency, with the latter defined as none, mild, or moderate
enal insufficiency based on GFR (8). After correlating the
ata to outcomes, renal insufficiency and diabetes were each
ssociated with higher risk. We are more aware of diabetes-
elated risk, but in this study renal insufficiency alone
roduced more clinical events than did diabetes mellitus
ithout renal insufficiency. Importantly, the two conditions
cted synergistically to confer still higher risk. It seems that
iabetes and renal insufficiency identify very high-risk pa-
ients who may require different therapies and procedures
fter ACS.
Prof. Keith Fox and his Edinburgh University team
ooked at the impact of renal dysfunction on the efficacy and
afety of fondaparinux versus enoxaparin in the 20,078
on–ST-segment elevation ACS patients from the
ASIS-5 trial (9). At nine days, mortality and bleeding
ates increased with each quartile of creatinine, with mor-
Table 1. EXTRACT–TIMI-25: 30-Day Effica
Outcomes
Primary efficacy end point (death or nonfatal MI)
Death
Nonfatal MI
Urgent revascularization
Death, nonfatal MI, or urgent revascularization
Data are presented as n (%).
MI  myocardial infarction.ality ranging from 0.97% in the lowest quartile to 3.12% in rhe highest (creatinine 1.2 mg/dl). Likewise, bleeding
ncreased from 2.7% to 4.8% in the highest quartile,
lthough hazard ratios for bleeding were consistently less
ith fondaparinux. Both six-month mortality and nine-day
leeding rates increased with the highest creatinine quartile
or both antithrombin agents, but again these rates were
onsistently lower for fondaparinux versus enoxaparin. In
he highest quartile, the six-month mortality rate was
ignificantly lower with fondaparinux (9.5% vs. 11.4%; p 
.02). The investigators concluded that rates of bleeding
ere influenced by baseline renal function with either
ntithrombin, and higher rates of mortality and bleeding
ssociated with enoxaparin versus fondaparinux were most
vident at the highest creatinine quartile. This suggests that
noxaparin may require more dose adjustments in the
resence of renal dysfunction.
IPID MANAGEMENT
n analysis of data from the National Health and Nutrition
xamination Survey offers the encouraging news that more
ndividuals seem to be managing their low-density lipopro-
ein (LDL) cholesterol. In analyzing data from 3,398
atients from the 1999 to 2000 data set compared with
,746 from the 2001 to 2002 subset, researchers found that
mong high-risk patients, those with an LDL 100 mg/dl
ncreased from 23% in the earlier period to 32% (p  0.01)
n the 2001 to 2002 subset (10). Considering just those
igh-risk patients with CAD, the percentage of patients
ith LDL levels 100 mg/dl increased from 27% to 41%
p  0.05), which was much better than patients without
eart disease, where there was only a trend toward better
DL management (20% to 26%; p  0.07). Also encour-
ging is that the percentage of all high-risk patients with
DL 130 mg/dl who were untreated decreased (36% vs.
7%; p  0.01); this time, the decrease was significant both
n patients with CAD (25% vs. 16%; p 0.05) and in those
ithout CAD (44% vs. 33%; p 0.01). This shows that we
re making headway in treating high-risk patients, although
here is still a long way to go to ensure adequate LDL
owering.
For an example of what we still need to work on, consider
sampling of 2004 data from 4,676 outpatients with CV
isease; the data were extrapolated to the U.S. population to
ee how well LDL goals were being reached after the
utcomes
oxaparin
10,256)
Unfractionated Heparin
(n  10,223) p Value
17 (9.9) 1,223 (12.0) 0.001
08 (6.9) 765 (7.5) 0.11
09 (3.0) 458 (4.5) 0.001
13 (2.1) 286 (2.8) 0.001
99 (11.7) 1,479 (14.5) 0.001cy O
En
(n 
1,0
7
3
2
1,1ecommendations of the National Cholesterol Education
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mately 67.2 million people in the U.S. have risk factors for
AD or other CV disease, whereas another 35.1 million
ave CAD or CAD equivalent. In comparing LDL levels
nd statin use with NCEP targets for each group, approx-
mately 60% of patients were receiving statin therapy, yet
8% still had LDL levels higher than NCEP III targets.
espite the fact that nearly half of treated patients were
learly not at their target level, only 7.1% were on high-dose
tatin therapy. So, even in the most recent data from 2004,
DL levels remain higher than NCEP goals in a substantial
umber of patients.
ENOMIC ASSOCIATION
hen et al. (12) of the Cleveland Clinic looked at the
enomic association of graft failure of the left internal
horacic artery-left anterior descending graft for myocardial
evascularization in 230 patients. At 5 years, 30 patients had
stenotic or occluded graft; an additional 11 were stenotic
r occluded at 10 years. The researchers analyzed 168
ingle-nucleotide polymorphisms from 150 vascular genes
nd found three single-nucleotide polymorphisms—F5,
TN, and MTP—that were significantly associated with
raft failure (p  0.01), whereas five others were associated
ith graft patency.
Several factors are thought to contribute to long-term
raft patency: coagulation, cell proliferation, inflammation,
nd lipid metabolism. The mechanisms describing how
hese factors affect graft patency are presently unknown, but
he work presented here may provide a glimpse into the
uture of medicine: using genetics to target both diagnosis
nd therapy.
TRATEGIES FOR DEALING WITH
YOCARDIAL INFARCTION
arious groups reported on strategies for treating MI
atients; in Sweden, Björkland et al. (13) looked at a
rospective cohort of consecutive STEMI patients who
ere ambulance-transferred to 66 different hospitals and
reated with primary PCI between 2002 and 2004. The
egistry data were used to evaluate the relationship between
prehospital diagnostic strategy, which included a prehos-
ital electrocardiogram (ECG), and outcome. A prehospital
CG was obtained in 911 patients and sent to the nearest
ospital, where the patient received triage care. These
atients were compared with a group of 1,106 with no
rehospital ECG. Median time to therapy with the prehos-
ital ECG was 55 min less (p  0.001), and these patients
ended to have a slightly lower 30-day mortality (2.4% vs.
.6%, p  0.12). Using multivariate analysis, use of a
rehospital ECG was associated with a risk reduction of
7%, suggesting that a prehospital diagnostic strategy may
e important, even when patients are triaged to primary
CI. Clearly, this is another example of the accepted adage Rhat time is myocardium and anything that shortens the
ime to reperfusion has the potential to improve outcomes.
A study from France considered whether the volume of
ercutaneous transluminal coronary angioplasty (PTCA)
nfluences the outcome of primary stenting or primary
reatment for STEMI, even in the era of stenting. The
reater Paris PTCA registry included 37,848 procedures in
4 centers in 2001 and 2002; 87% of patients received stents
14). Morice et al. (14) correlated in-hospital mortality with
he PTCA volume in both low- and high-risk patient
ubsets. High-risk patients were predefined as MI 24 h,
ardiogenic shock, or out-of-hospital cardiac arrest.
High-risk patients had higher mortality rates in low-
olume centers (400 PTCAs annually; 8.54% vs. 6.75%;
 0.28); mortality was the same for low-risk patients
egardless of the volume of procedures performed at a
enter. Using multivariate analysis, predictors of death
ncluded age, female gender, annual volume, and high-risk
rocedures. Treatment at low-volume centers was also
ssociated with a higher rate of complications. Thus, even in
he era of widespread stenting, PTCA volume remains a
actor in outcomes, and the investigators warned against
romoting intervention in new hospitals with low numbers.
nfortunately, in this study no data were provided on
ndividual physician statistics.
Another study followed up 500 patients treated with
rug-eluting stents to determine the incidence and predic-
ors of discontinuation of thienopyridine therapy one month
fter stenting for acute MI (15). Approximately 13.6% of
he patients were no longer taking thienopyridines 30 days
fter drug-eluting stent placement. There were several
nivariate predictors of discontinuation (Table 2), but on
ultivariate analysis, only limited education was statistically
ignificant. This is an important problem: in this particular
tudy, mortality between 1 and 12 months was 7.5% in
hose who had stopped therapy versus 0.7% (p  0.001) for
hose continuing therapy; hospitalizations were also higher
ith drug discontinuation (23% vs. 14%; p  0.08). The
esults show that although discontinuation of therapy is a
ommon problem, the ability to predict it happening is
able 2. Univariate Predictors of Thienopyridine Therapy
iscontinuation
Characteristic
Thienopyridine Therapy
p ValueDiscontinue Continue
lder age (yrs) 64 60 0.03
ompleted high school 73% 89% 0.001
arried 56% 71% 0.01
void health care due to cost 24% 13% 0.02
rior vascular disease 49% 30% 0.003
ung disease 18% 8% 0.02
nemia at presentation 19% 7% 0.001
eceived discharge instructions
about medication
88% 95% 0.05eferred for cardiac rehabilitation 50% 64% 0.03
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eeping patients from discontinuing therapy are needed.
ORCINE STEM CELLS
inally, the transplantation of stem cells after MI is prom-
sing, but the literature is inconsistent, with some studies
uggesting benefit and others indicating little or no clinical
alue. In a study from Tulane University, researchers stud-
ed the effect of adipose-derived stem cells, which are more
revalent than bone marrow-derived stem cells, in a porcine
odel (16). After occluding the left anterior descending
rtery for 3 h, investigators injected stem cells distally
hrough the balloon catheter and then killed the animals 8
eeks later. Left ventricular wall thickness was significantly
hicker in the infarct zone in those given the stem cells
ersus controls (5.9 mm vs. 3.6 mm) as well as in the border
one. Additionally, the treated pigs showed an increase in
apillary density in the border zone (p  0.05). Nuclear
jection fractions were 7% higher in the stem cell-treated
igs, and there was a lower end-diastolic volume. These
ata are promising and suggest a need for further studies to
etermine the role for adipose-derived stem cells to improve
yocardial function after an MI; perhaps the effects are
rimarily attributable to reduced remodeling.
In summary, this meeting was full of new and significant
andomized clinical trial data as well as interesting and
mportant information in the abstracts. I extend my con-
ratulations to all those involved.
eprint requests and correspondence: Dr. John A. Ambrose,
CSF-Fresno, 445 South Cedar, Fresno, California 93702.
-mail: jamambrose@yahoo.com.
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